Immunogenicity and Safety of AVAXIM™ 80U-Pediatric Administered Alone or Concomitantly With TRIMOVAX™ in 12-13 Months Old Healthy Hepatitis A Seronegative Turkish Children

NCT00313950 Phase 4 COMPLETED

The present study will explore the immunogenicity of AVAXIM™ 80U-Pediatric in 12-13 months Turkish children and check if the administration of the MMR trivalent vaccine on the same day but at different site will interfere on immunogenicity for the four valences Hepatitis A, Measles, Mumps, and Rubella.

Details

Lead sponsor	Sanofi Pasteur, a Sanofi Company
Phase	Phase 4
Status	COMPLETED
Enrolment	470
Start date	2006-09
Completion	2010-04

Conditions

• Measles
• Mumps
• Rubella
• Hepatitis A

Interventions

• Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella
• Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine
• Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella

Primary outcomes

• To provide information concerning the immunogenicity of Hepatitis A Vaccine in subjects receiving Pediatric vaccines. — Day 7 - Day 196

Countries

Turkey (Türkiye)